Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. - Wikidata - awgldk - TriplyDB

Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

http://www.wikidata.org/entity/Q53253353

about

Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes Vogt-Koyanagi-Harada syndrome - current perspectives.Comparison of the optical coherence tomographic characters between acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy.Influence of molecular genetics in Vogt-Koyanagi-Harada disease.Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings.Headache as an initial manifestation of Vogt-Koyanagi-Harada disease Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease Rituximab in refractory Vogt-Koyanagi-Harada disease.Indocyanine green angiography findings in patients with long-standing Vogt-Koyanagi-Harada disease: a cross-sectional study.Reversible alopecia in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.Vogt-Koyanagi-Harada disease in Thailand.Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.Auditory and vestibular manifestations of Vogt-Koyanagi-Harada disease.Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada disease: clinical and demographic characteristics of patients in a specialized eye hospital in Turkey.Late onset acute Vogt-Koyanagi-Harada syndrome-challenges on the way.A challenging case of tuberculosis-associated uveitis after corticosteroid treatment for Vogt-Koyanagi-Harada disease

P2860

Q26752297-65D94C60-5C09-47A1-ACB8-6C908D9F5949 Q28072882-3A696ECD-30D5-40CF-A5CB-0735D0711BBB Q33904800-3EDCB692-B068-4D12-A7BF-83776CC29121 Q33929571-68583707-B81A-4D58-B678-4895BBF46F81 Q33989519-5791F1C6-37F2-450C-9DE6-E0BC95BEEFD7 Q34274659-BECC8AD4-95F3-475D-8307-175BB35F2630 Q35555776-A785375C-1439-4315-A717-E606CE9A06DB Q35571023-9A205F2E-D278-4105-9A05-F8C8197E8240 Q36346347-B39C856F-A62B-4C0F-96F0-9D6C72795D11 Q36750361-8804D73F-DE56-4FED-8152-DAE24CB562D3 Q36925622-94741ADE-AE2E-4422-ADE8-DF48A5FCF733 Q37830790-89DA6D99-A33C-4E5A-8037-3EBD7DA511B9 Q38060844-24131E9D-6C0A-432A-BCD8-A2B1EAFE39D9 Q38591885-FABFDCDA-1FB5-4275-ABE6-B9BB6BE29F03 Q39008824-6FC1A972-1592-477F-93D1-B2CBB0BFFC83 Q40703622-1B91A79A-7986-4315-8892-38509C7D1185 Q41405377-713A16EC-9405-4A3E-A477-C0FABE305B7A Q41614992-E7585BB8-73A9-4675-B524-07209B212FE1 Q43060159-FB03538E-E220-4B89-BE2F-874204E60D32 Q46419310-DB52EF46-F8CD-4D29-B86C-A782979F49B0 Q46680282-7C6F2571-D0D0-4A19-A702-0568B5B059C2 Q47654494-9D62951E-CF7A-4687-9487-0813F1C472B3 Q50436391-59C318EC-FA8A-4F02-9173-F05632301698 Q50485692-623CBE18-03D3-4368-9D4B-332510B8BCF7 Q50746452-A8ED28C4-680C-4119-8606-A088FAE7FF2B Q51177631-CE650AA1-16E0-4AB8-B88F-992A27310E17 Q55373402-7E918E31-38A7-48B6-BFD9-8DFDCE68912D Q58767210-456600AC-3C49-4BE5-8CBA-025DB9524757

P2860

Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.

http://www.wikidata.org/entity/Q53253353

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@en

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@nl

type

label

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@en

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@nl

prefLabel

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@en

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@nl

P1433

Q53253353-F7275F29-FA30-476B-B8D3-3836DE52DCEA

P1476

Q53253353-63F42BB2-CE93-4C6E-803D-BAB63F190DD1

P2093

Q53253353-0BF76C42-421F-4AFC-A9BA-BB0298DF546C

Q53253353-16032D1E-61F3-473F-B2BB-E72F483EBD29

Q53253353-20E5EB73-73D0-450F-BAC5-4D39DCAA09EF

Q53253353-2753ECF9-CE05-45B4-BE32-61746A2C13DC

Q53253353-31C60FDC-49B8-42FA-A7CB-C8F82426E7E0

Q53253353-49225DBD-786C-4EB4-9D65-2E2A95975A65

Q53253353-4FE42AE4-3920-42C0-91A4-7B3B8642E0AD

Q53253353-527AB719-98CC-4452-BFD7-9137153F2188

Q53253353-5856F0FE-CC9F-4284-9738-BF8F7928F66C

Q53253353-6BE6BAA3-CB00-405F-9FCB-C2F4CFBFFEB9

P304

Q53253353-2811BB99-8773-4C4B-BBA7-33371442BEE9

P31

Q53253353-BC30F762-3AC5-4CB7-A840-4A45D3C291A0

P356

Q53253353-03C912E9-55C5-46C0-AAC6-E9FBB6A497E8

P407

Q53253353-5A212216-EB44-49A7-B6FF-F11A90D5E53C

P433

Q53253353-E6DA3D65-DCA3-413A-A925-0749963CDCEF

P478

Q53253353-18D4E4F4-0B64-4A4A-8852-06394794E5AC

P50

Q53253353-7B7B3006-106E-4752-8055-554C7C4837C4

Q53253353-A588A46D-5478-493C-9698-DC281DDA3D2B

P577

Q53253353-F8F92DC2-6D8B-4E7A-B316-446F3C24ADAB

P698

Q53253353-1E61B38D-C30C-4524-89AE-A3FABE244F77

P356

J.AJO.2006.02.049

P1433

American Journal of Ophthalmology

P1476

Evaluation of the effect on ou ...... Vogt-Koyanagi-Harada disease.

@en

P2093

Annabelle A Okada

http://www.w3.org/2001/XMLSchema#string

Antonio Secchi

http://www.w3.org/2001/XMLSchema#string

Christine Fardeau

http://www.w3.org/2001/XMLSchema#string

Claire Lemaitre

http://www.w3.org/2001/XMLSchema#string

Eri Kojima

http://www.w3.org/2001/XMLSchema#string

Fei Yu

http://www.w3.org/2001/XMLSchema#string

Gary N Holland

http://www.w3.org/2001/XMLSchema#string

Hidetoshi Kawashima

http://www.w3.org/2001/XMLSchema#string

Hiroshi Goto

http://www.w3.org/2001/XMLSchema#string

Khalid F Tabbara

http://www.w3.org/2001/XMLSchema#string

P304

119-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJO.2006.02.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16815259

http://www.w3.org/2001/XMLSchema#string